Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.80 |
| ▸ | NT5E | P21589 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | CES2 | O00748 | 2/20 | 0.70 |
| ▸ | CES1 | P23141 | 2/20 | 0.70 |
| ▸ | F3 | P13726 | 1/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.65 |
| ▸ | GLI1 | P08151 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.65 |
| ▸ | ALB | P02768 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.65 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.65 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15450723 | 1.00 | GPBAR1 (0.80) | GPBAR1NT5ELMNASMN1; SMN2CES2 | |
| SCHEMBL14554424 | 1.00 | GPBAR1 (0.80) | GPBAR1NT5ELMNASMN1; SMN2CES2 | |
| SCHEMBL14023068 | 1.00 | GPBAR1 (0.80) | GPBAR1NT5ELMNASMN1; SMN2CES2 | |
| SCHEMBL16704974 | 1.00 | GPBAR1 (0.80) | GPBAR1NT5ELMNASMN1; SMN2CES2 | |
| SCHEMBL14134274 | 1.00 | GPBAR1 (0.80) | GPBAR1NT5ELMNASMN1; SMN2CES2 | |
| SCHEMBL3507861 | 1.00 | GPBAR1 (0.80) | GPBAR1NT5ELMNASMN1; SMN2CES2 | |
| SCHEMBL13184576 | 1.00 | GPBAR1 (0.80) | GPBAR1NT5ELMNASMN1; SMN2CES2 | |
| SCHEMBL14134563 | 0.94 | GPBAR1 (0.81) | GPBAR1NT5ELMNASMN1; SMN2CES2 | |
| SCHEMBL16704632 | 0.94 | GPBAR1 (0.69) | GPBAR1NT5ELMNASMN1; SMN2CES2 | |
| SCHEMBL15445087 | 0.94 | GPBAR1 (0.69) | GPBAR1NT5ELMNASMN1; SMN2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4529452-B1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | GIULIANI SPA (IT) | 2025-12-24 | — | — | EP | claimed |
| US-20250170038-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | GIULIANI S.P.A. (IT) | 2025-05-29 | — | — | US | claimed |
| EP-4529452-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | Giuliani S.p.A. (IT) | 2025-04-02 | — | — | EP | claimed |
| WO-2023228079-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | GIULIANI S.P.A. (IT) | 2023-11-30 | — | — | WO | claimed |
| EP-4529452-B1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | GIULIANI SPA (IT) | 2025-12-24 | — | — | EP | disclosed |
| US-20250170038-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | GIULIANI S.P.A. (IT) | 2025-05-29 | — | — | US | disclosed |
| EP-4529452-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | Giuliani S.p.A. (IT) | 2025-04-02 | — | — | EP | disclosed |
| CN-119654128-A | Dosage forms for topical administration of pentacyclic triterpenes | 朱利亚尼股份公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023228079-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | GIULIANI S.P.A. (IT) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170038-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | MAS1, CYP51A1, EYA2 | GPBAR1 1876/4885NT5E 2951/4885LMNA 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.